Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

The Lancet Oncology

Volumn 17, Issue 9, 2016, Pages 1283-1294

  Younes, Anas ^a   Santoro, Armando ^b   Shipp, Margaret ^c   Zinzani, Pier Luigi ^d   Timmerman, John M ^e   Ansell, Stephen ^f   Armand, Philippe ^c   Fanale, Michelle ^g   Ratanatharathorn, Voravit ^h   Kuruvilla, John ⁱ   Cohen, Jonathon B ^j   Collins, Graham ^k   Savage, Kerry J ^l   Trneny, Marek ^m   Kato, Kazunobu ⁿ   Farsaci, Benedetto ⁿ   Parker, Susan M ⁿ   Rodig, Scott ^o   Roemer, Margaretha G M ^c   Ligon, Azra H ^o   Engert, Andreas ^p   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MAYO CLINIC   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h KARMANOS CANCER INSTITUTE   (United States)

ⁱ PRINCESS MARGARET HOSPITAL   (Canada)

^j EMORY UNIVERSITY   (United States)

^k CHURCHILL HOSPITAL   (United Kingdom)

^l BRITISH COLUMBIA CANCER AGENCY   (Canada)

^m CHARLES UNIVERSITY   (Czech Republic)

ⁿ BRISTOL MYERS SQUIBB   (United States)

^o BRIGHAM AND WOMEN S HOSPITAL   (United States)

^p UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; BRENTUXIMAB VEDOTIN; NIVOLUMAB; TRIACYLGLYCEROL LIPASE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADULT; ANEMIA; ARTHRALGIA; ARTHRITIS; ARTICLE; AUTOIMMUNE HEPATITIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACKACHE; BODY WEIGHT; BONE NECROSIS; BRONCHOPNEUMONIA; CAUSE OF DEATH; CLASSICAL HODGKIN LYMPHOMA; COHORT ANALYSIS; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EMBOLISM; EUROPE; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GENERALIZED EDEMA; HEADACHE; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; INFUSION RELATED REACTION; LEUKOPENIA; LUNG INFECTION; LYMPHOCYTE COUNT; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; NORTH AMERICA; PERICARDIAL EFFUSION; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SKIN INFECTION; THROMBOCYTE COUNT; TREATMENT FAILURE; TUMOR GROWTH; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ADVERSE EFFECTS; AUTOTRANSPLANTATION; CANCER STAGING; CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS;

EID: 84994525384     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30167-X     Document Type: Article

References (23)

1. 1 Swerdlow, SH, Campo, E, Harris, NL, et al. (eds.) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn., 2008, World Health Organization, Geneva.
2. 2 Schmitz, N, Pfistner, B, Sextro, M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 359 (2002), 2065–2071.
3. 3 Martinez, C, Canals, C, Sarina, B, et al. Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation. Ann Oncol 24 (2013), 2430–2434.
4. 4 Arai, S, Fanale, M, DeVos, S, et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma 54 (2013), 2531–2533.
5. 5 Younes, A, Gopal, AK, Smith, SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 30 (2012), 2183–2189.
6. 6 Cheah, CY, Chihara, D, Horowitz, S, et al. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol 27 (2016), 1317–1323.
7. 7 Kuppers, R, The biology of Hodgkin's lymphoma. Nat Rev Cancer 9 (2009), 15–27.
8. 8 Chen, BJ, Chapuy, B, Ouyang, J, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 19 (2013), 3462–3473.
9. 9 Green, MR, Monti, S, Rodig, SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116 (2010), 3268–3277.
10. 10 Roemer, MGM, Advani, RH, Ligon, AH, et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol, 2016, 10.1200/JCO.2016.66.4482 published online April 11.
11. 11 Steidl, C, Shah, SP, Woolcock, BW, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 471 (2011), 377–381.
12. 12 Freeman, GJ, Long, AJ, Iwai, Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192 (2000), 1027–1034.
13. 13 Yamamoto, R, Nishikori, M, Kitawaki, T, et al. PD-1–PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 111 (2008), 3220–3224.
14. 14 Weber, JS, D'Angelo, SP, Minor, D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16 (2015), 375–384.
15. 15 Borghaei, H, Paz-Ares, L, Horn, L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
16. 16 Motzer, RJ, Escudier, B, McDermott, DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (2015), 1803–1813.
17. 17 Ansell, SM, Lesokhin, AM, Borrello, I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372 (2015), 311–319.
18. 18 Ansell, SM, Armand, P, Timmerman, JM, et al. Nivolumab in patients (pts) with relapsed or refractory classical Hodgkin lymphoma (R/R cHL): clinical outcomes from extended follow-up of a phase 1 study (CA209-039). Blood, 126, 2015, 583.
19. 19 Cheson, BD, Pfistner, B, Juweid, ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 25 (2007), 579–586.
20. 20 Pickard, AS, Neary, MP, Cella, D, Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes, 5, 2007, 70.
21. 21 Center for Drug Evaluation and Research. Clinical review: Adcetris (brentuximab vedotin). Biologics License Application (BLA) 125388. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125388Orig1s000MedR.pdf (accessed March 18, 2016).
22. 22 Griffeth, LK, Use of PET/CT scanning in cancer patients: technical and practical considerations. Proc (Bayl Univ Med Cent) 18 (2005), 321–330.
23. 23 Barrington, SF, Mikhaeel, NG, When should FDG-PET be used in the modern management of lymphoma?. Br J Haematol 164 (2014), 315–328.